Why is "5N-Bicalutamide" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-02 01:57:29
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
5N-Bicalutamide entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-02 and was most recently seen on 2026-06-02.
Wikipedia Overview
5N-Bicalutamide, or 5-azabicalutamide, is a highly potent nonsteroidal antiandrogen (NSAA) which was discovered in 2016. It is a structural modification of bicalutamide, differing from it only by the replacement of a carbon atom with a nitrogen atom in one of its phenyl rings. Similarly to bicalutamide, the drug acts as a selective antagonist of the androgen receptor (AR). However, unlike bicalutamide, it is a reversible covalent antagonist and stays bound to the receptor for a far longer amount of time. As a result of this difference, 5N-bicalutamide has markedly improved potency relative to bicalutamide, with approximately 150-fold higher affinity for the AR (Ki = 0.15 nM versus 22.3 nM) and about 20-fold greater functional inhibition (IC50Tooltip Half-maximal inhibitory concentration = 15 nM versus 310 nM) of the AR. Future studies of 5N-bicalutamide in normal and mutated prostate cancer cells are planned or underway and it is anticipated that N-bicalutamide may be able to overcome resistance to current antiandrogens that are used in the treatment of prostate cancer.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Structural basis for antagonism and resistance of bicalutamide in prostate cancer - PNAS
-
Antiandrogen Therapy Radiosensitizes Androgen Receptor–Positive Cancers to 18F-FDG - Journal of Nuclear Medicine
-
Bicalutamide and trehalose show promise in mouse model of SBMA |... - SMA News Today
-
FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer - PR Newswire
-
The Current Landscape of Metastatic Hormone Sensitive Prostate Cancer: A Plethora of Treatment Options - UroToday
-
Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells - Nature
-
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells - PNAS
-
The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells - Nature
-
Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.